HDL acquires license for lung cancer detection test
Richmond-based Health Diagnostic Laboratory Inc. is expanding its health screenings to include testing for lung cancer.
HDL announced Tuesday that it has acquired substantially all the assets of a U.S. subsidiary of Britain-based Onciummune Ltd., which developed a blood test used for risk assessment and early detection of lung cancer.
HDL, which offers tests determining the risk factors associated with cardiovascular disease and diabetes, will have the exclusive license to market and perform EarlyCDT-Lung testing in the U.S. Terms of the agreement were not disclosed.
“Since the beginnings of Health Diagnostic Laboratory five years ago, we have always said that our model of early detection and prevention for cardiovascular disease is a platform to do the same with other diseases and chronic conditions, and this agreement with Oncimmune pushes us deeper into that mission by expanding our focus to include lung cancer,” Tonya Mallory, HDL Inc.'s president and CEO, said in a statement.
Oncimmune USA is based in De Soto, Kan. The company’s 25 employees will join HDL, which has more than 700 employees in the Richmond area.